

CONTENTS

CHAPTER 1	Introduction and outline	13
CHAPTER 2	Methodological considerations in quantification of 3'-deoxy-3'-[¹⁸ F]fluorothymidine uptake measured with positron emission tomography in patients with non-small cell lung cancer. <i>Mol Imaging Biol. 2014 Feb;16(1):136-45</i>	27
CHAPTER 3	Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸ F]fluorothymidine positron emission tomography. <i>PLoS ONE. 2013 May;24:8(5):e63705</i>	53
CHAPTER 4	Assessment of simplified methods to measure 3'-deoxy-3'-[¹⁸ F]fluorothymidine uptake changes in EGFR mutated non-small cell lung cancer patients undergoing EGFR tyrosine kinase inhibitor treatment. <i>J Nucl Med. 2014 in press</i>	79
CHAPTER 5	Repeatability of metabolically active volume measurements with [¹⁸ F]FDG and [¹⁸ F]FLT PET in non-small cell lung cancer. <i>J Nucl Med. 2010 Dec;51(12):1870-7</i>	101

CHAPTER 6	Repeatability of metabolically active tumor volume measurements with FDG PET/CT in advanced gastrointestinal malignancies: a multicenter study. <i>Radiology. 2014 May;26:132807</i>	123
CHAPTER 7	General discussion and future perspectives	149
ADDENDUM	List of abbreviations	171
	Dutch summary	175
	Acknowledgements	181
	Curriculum vitae	187
	List of publications	189